ADCC-Enhanced Anti-Human HER2 ([vic-]trastuzumab) Antibody, a biobetter (CAT#: BioBet-CB-033LX) Datasheet

Target
HER2
Isotype
IgG1
Description
ADCC-Enhanced Anti-Human HER2 ([vic-]trastuzumab) Antibody is a glycosylation-modified anti- therapeutic antibody. Creative Biolabs' Afuco™ technology platform allows control of glycosylation level, thereby achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Patent
NCT03262935

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ERBB2
Full Name
erb-b2 receptor tyrosine kinase 2
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Alternative Names
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Gene ID
UniProt ID
Field of research
Cell Biology, Immunology,
Trade name
[vic-]trastuzumab
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
[vic-]trastuzumab
Host
Humanized
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human HER2 ([vic-]trastuzumab) Antibody is derived from clone [vic-]trastuzumab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the HER2, and it is intended for the research of Breast cancer .
Indication
Breast cancer

Similar to the parental antibody [vic-]trastuzumab, ADCC-Enhanced Anti-Human HER2 ([vic-]trastuzumab) Antibody targets to the antigen HER2, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK